Andrea Oliva | EEA & UK QPPV
Viatris

Andrea Oliva is an experienced pharmacovigilance leader currently serving as EEA & UK QPPV at Viatris in Milan.
Prior to this appointment, he held the position of Head of Pharmacovigilance for Italy at Viatris from July 2017 to February 2026, where he acted as the local pharmacovigilance contact.
He also worked as Local Pharmacovigilance Manager at Boehringer Ingelheim Italia, where he was responsible for both human and veterinary pharmacovigilance activities and contributed to cross-functional SOP simplification initiatives as a committee member. Earlier in his career, Andrea gained extensive consulting experience at GB Pharma as EU QPPV for multiple marketing authorization holders, supporting audit and inspection readiness, signal detection, and preparation of key safety reports such as RMPs, PSURs, and DSURs, while also contributing to regulatory strategy and labeling activities.
He began his pharmacovigilance path as a Drug Safety Officer and progressed through roles in regulatory affairs, including experience with variations, renewals, and dossier submissions at DOC Generici and Teofarma.  In addition to his industry career, Andrea has been actively engaged in academia since 2013 as a lecturer in pharmacovigilance at several Italian universities, sharing expertise with students in pharmacy and pharmaceutical sciences.  He holds a PhD in Pharmacovigilance and Pharmacoepidemiology from the EU2P program at the University of Bordeaux, complemented by a Master’s degree in Biology Applied to Clinical Research and a degree in Pharmaceutical Biotechnology from the University of Milan.  Andrea has contributed to the scientific community through multiple publications, including research on the safety profile of trastuzumab and the quality of adverse drug reaction reporting, as well as participation in international congresses and pharmacovigilance forums.  Overall, Andrea Oliva combines over 15 years of experience in pharmacovigilance and regulatory affairs with academic involvement and scientific contributions, positioning him as a highly skilled professional in drug safety and risk management at both local and international levels